摘要
目的探讨尼莫地平对帕金森病(PD)患者认知功能障碍的改善作用。方法将106例合并认知功能障碍的PD患者随机分为对照组(给予美多巴、森福罗等治疗)及治疗组(在对照组治疗的基础上,加用尼莫地平30 mg,3次/d),并随访至治疗12 w末。分别在治疗前及治疗后第4、8、12 w末进行蒙特利尔认知评估量表(MoCA)评分。结果两组患者治疗前MoCA评分间差异无统计学意义(P>0.05);治疗后4、8、12 w末,治疗组MoCA评分逐渐提高,显著高于治疗前(P<0.01),而对照组MoCA评分无显著变化(P>0.05),且低于治疗组(P<0.05)。结论尼莫地平能有效改善合并认知功能障碍的PD患者的认知功能。
Objective To explore the improvement effects of nimodipine on cognitive dysfunction of patients with Parkinson＇s disease（PD）.Methods 106 patients with PD combined with cognitive dysfunction were randomly divided into control group（receiving the medication with madopar and sifrol）and treatment group（receiving 30 mg nimodipine 3 times/d based on the same medication as the control group）.Follow-up was made during the 12 weeks of treatment.The Montreal Cognitive Assessment Scale score（MoCA）was conducted 4,8 and 12 w before and after the treatment.Results Before the treatment,there was no significant difference in MoCA scores between the two groups（P0.05）.After the treatment,the score at the end of 4,8 and 12 w in the treatment group increased gradually and was significantly higher than that before the treatment（P0.01）.However,there was no significant difference in MoCA score of the control group before and after the treatment（P0.05）,and the score after the treatment was lower than that of the treatment group（P0.05）.Conclusion Nimodipine can effectively improve the cognitive function in patients with Parkinson＇s disease combined with cognitive dysfunction.
出处
《西南国防医药》
CAS
2012年第5期498-500,共3页
Medical Journal of National Defending Forces in Southwest China
关键词
尼莫地平
帕金森病
认知功能障碍
nimodipine
Parkinson＇s disease
cognitive dysfunction
